Literature DB >> 1700486

Autism: review of neurochemical investigation.

E H Cook1.   

Abstract

The neurochemistry of autism, the most well-validated childhood neuropsychiatric disorder, has been studied extensively over the past three decades. Autism is of interest neurochemically because it represents a relatively homogeneous disorder with a triad of social, communicative, and intellectual developmental disturbance. Because a sufficient animal model has been lacking and relatively few diagnosed people with autism have died, most investigation has been of peripheral fluids and tissues. The most consistent finding has been that over 25% of autistic children and adolescents are hyperserotonemic. However, after 29 years of investigation, the mechanism of hyperserotonemia has not been determined. Hyperserotonemia has been found to be familial. Elevated plasma norepinephrine has also been a replicated finding. Cerebrospinal fluid (CSF) opiate activity has been found to be elevated in two studies. Plasma cyclic adenosine monophosphate (cAMP) has been found to be elevated in autistic children. A high rate of nonsuppression after dexamethasone and blunted or delayed growth hormone response to L-dopa have been found. Abnormal cell-mediated immunity has been replicated consistently in autism. Although several pharmacological trials have been conducted and shown promise in initial open trials, only "typical" antipsychotic drugs have shown replicable chronic ameliorating effects in double-blind trials. However, chronic neurotoxicity (tardive dyskinesia) has also been revealed. Findings of morphological changes in the cerebellum have been replicated. Findings in need of replication include diminished platelet function, increased baseline CSF homovanillic acid, decreased nerve cell adhesion molecule serum fragment, blunted prolactin response to fenfluramine, amelioration of symptoms by naltrexone and bromocriptine, reduced electroretinographic (ERG) b-wave amplitude, and morphological changes in the hippocampus, amygdala, and septal nuclei. In addition to refining and replicating past findings, future directions that may be fruitful include investigation of neurochemical aspects of platelet function, of interactions between monoaminergic systems, of phosphatidylinositides, and of pharmacological response to "atypical" antipsychotic agents and relatively selective serotonin receptor subtype agonists or antagonists.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1700486     DOI: 10.1002/syn.890060309

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  24 in total

1.  Pupil and salivary indicators of autonomic dysfunction in autism spectrum disorder.

Authors:  Christa J Anderson; John Colombo; Kathryn E Unruh
Journal:  Dev Psychobiol       Date:  2012-05-29       Impact factor: 3.038

2.  Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism.

Authors:  Yoko Sugie; Hideo Sugie; Tokiko Fukuda; Masataka Ito; Yumiko Sasada; Mutsumi Nakabayashi; Kazunobu Fukashiro; Takehiko Ohzeki
Journal:  J Autism Dev Disord       Date:  2005-06

Review 3.  The power and promise of identifying autism early: insights from the search for clinical and biological markers.

Authors:  Karen Pierce; Stephen J Glatt; Gregory S Liptak; Laura Lee McIntyre
Journal:  Ann Clin Psychiatry       Date:  2009 Jul-Sep       Impact factor: 1.567

Review 4.  Brief report: pathophysiology of autism: neurochemistry.

Authors:  E H Cook
Journal:  J Autism Dev Disord       Date:  1996-04

Review 5.  Etiology of infantile autism: a review of recent advances in genetic and neurobiological research.

Authors:  G Trottier; L Srivastava; C D Walker
Journal:  J Psychiatry Neurosci       Date:  1999-03       Impact factor: 6.186

6.  Brief report: four case histories and a literature review of Williams syndrome and autistic behavior.

Authors:  C Gillberg; P Rasmussen
Journal:  J Autism Dev Disord       Date:  1994-06

7.  Brain effects of chronic IBD in areas abnormal in autism and treatment by single neuropeptides secretin and oxytocin.

Authors:  Martha G Welch; Thomas B Welch-Horan; Muhammad Anwar; Nargis Anwar; Robert J Ludwig; David A Ruggiero
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

8.  Plasma amino acid levels in children with autism and their families.

Authors:  Sarah Aldred; Kieran M Moore; Michael Fitzgerald; Rosemary H Waring
Journal:  J Autism Dev Disord       Date:  2003-02

9.  Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial.

Authors:  S H Fatemi; G M Realmuto; L Khan; P Thuras
Journal:  J Autism Dev Disord       Date:  1998-08

Review 10.  [Autism spectrum disorders. Current knowledge and importance for ENT specialists].

Authors:  C Schwemmle; U Schwemmle; M Ptok
Journal:  HNO       Date:  2008-02       Impact factor: 1.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.